Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Cullinan Therapeutics (NASDAQ:CGEM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at Wedbush from $25.00 to $34.00. They now have an "outperform" rating on the stock.
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting